https://doi.org/10.4081/hmr.v2i7.405

Monoclonal antibodies in the treatment of chronic lymphocytic leukemia

Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
Published: June 8, 2009
Abstract Views: 202
PDF: 182
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

MJ Keating
support@pagepress.org
The introduction of monoclonal antibodies into the therapeutic arena in chronic lymphocytic leukemia (CLL) has revolutionize the possibility of effective treatment of this indolent condition. The impressive activity of rituximab in the management of lymphoma was obvious early. The usefulness of this antibody in CLL was not as apparent, as in the pivotal clinical trial, small lymphocytic lymphoma (SLL) patients in relapse had a response rate of only 12%. Alemtuzumab when used initially had impressive antitumor activity but very significant toxicity. These two agents are however been built into effective treatment strategies at all ends of the therapeutic spectrum in CLL.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Keating, M. (2009). Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.405
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).